UAE Interventional Cardiology Devices Market, By Product Type (Angioplasty Balloons, Angioplasty Stents, Structural Heart Devices, Catheters, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, Others), By End User (Hospitals & Clinics, Ambulatory Surgery Centers, Others), By Region, Competition, Forecast and Opportunities, 2019-2029F
Market Report I 2024-09-29 I 87 Pages I TechSci Research
UAE Interventional Cardiology Devices Market was valued at USD 55.34 Million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.06% through 2029. The UAE interventional cardiology devices market represents a vital segment within the broader healthcare sector, driven by several key factors. And the rising facilities leads to the growth of cardiovascular devices market. For instance, In October 2022, FibriCheck collaborated with Pfizer and Altibbi to initiate an awareness campaign aimed at identifying atrial fibrillation (AF) in the UAE. The campaign focuses on raising awareness about AF detection using innovative digital health solutions. FibriCheck's technology allows users to monitor their heart rhythm remotely through smartphone apps, enabling early detection of irregularities. Partnering with Pfizer and Altibbi enhances outreach efforts and underscores the importance of proactive AF screening in improving cardiovascular health across the Emirates. As a dynamic and rapidly evolving market, it encompasses a variety of devices crucial for diagnosing and treating cardiovascular diseases (CVDs), which remain a leading cause of mortality in the region. Angioplasty stents, including bare-metal and drug-eluting variants, are pivotal in restoring blood flow to blocked arteries, thereby reducing the risk of heart attacks and improving patient outcomes. Their dominance is underscored by continuous advancements in stent design, materials, and coatings, aimed at enhancing efficacy and reducing complications like restenosis.
Also, Catheters play a critical role in guiding interventional procedures such as angioplasty and stent placement, ensuring precision and safety during operations. Structural heart devices, including transcatheter heart valves and closure devices, cater to a growing demand for minimally invasive treatments of congenital heart defects and valve disorders. Plaque modification devices and hemodynamic flow alteration devices further complement these advancements, offering innovative solutions to manage complex cardiovascular conditions.
The market's growth is bolstered by factors such as rising incidences of lifestyle-related diseases, increasing healthcare expenditure, and government initiatives to expand healthcare infrastructure. Moreover, the UAE's position as a hub for medical tourism further drives demand for cutting-edge interventional cardiology procedures and devices. With ongoing technological innovations and strategic investments, the UAE interventional cardiology devices market is poised for continued expansion, contributing significantly to improving cardiovascular care and patient outcomes across the Emirates.
Key Market Drivers
Increasing Prevalence of Cardiovascular Diseases
The increasing prevalence of cardiovascular diseases (CVDs) in the UAE underscores the critical importance of the interventional cardiology devices market. Lifestyle factors such as sedentary lifestyles, high-calorie diets, and stress contribute significantly to the rising incidence of CVDs, including coronary artery disease, hypertension, and heart failure among the UAE population. These conditions not only affect older adults but are increasingly prevalent among younger age groups due to changing dietary habits and reduced physical activity. In response to this health challenge, the demand for advanced interventional cardiology devices such as angioplasty stents, catheters, and structural heart devices has grown substantially. These devices are essential for diagnosing and treating various cardiovascular conditions, offering minimally invasive solutions that reduce recovery times and improve patient outcomes. The UAE's healthcare infrastructure has adapted to accommodate this demand, with hospitals and specialized cardiac centers equipped with state-of-the-art technology and skilled healthcare professionals capable of performing complex interventional procedures. According to the research article published in National Institute of Health, 2023, Cardiovascular diseases (CVDs) rank among the primary causes of death worldwide and contribute to 40% of mortality in the United Arab Emirates (UAE). The recent UAE National Health Survey underscored CVDs as a major health concern, highlighting physical inactivity, hypertension, obesity, and tobacco use as leading risk factors for CVD-related fatalities. The UAE Health Vision 2021 prioritizes reducing CVD risk factors and mortality rates, prompting substantial funding allocation towards cardiovascular research initiatives. As the prevalence of CVDs continues to rise, driven by demographic changes and lifestyle factors, the interventional cardiology devices market in the UAE is poised for further expansion. Continued innovation in device technology and increased access to specialized cardiac care are essential to meet the evolving healthcare needs of the population and mitigate the impact of cardiovascular diseases on public health. Also, according to the research article published in National Institute of Health, 2024, in the UAE, approximately 71% of adults and over 30% of children are affected by overweight or obesity. Statistics also indicate that the country has the world's second highest prevalence of diabetes, impacting 18.7% of the population, and a notable smoking rate with 9.1% of residents being smokers. These figures underscore the urgency to allocate greater resources towards researching lifestyle factors that contribute to cardiovascular disease (CVD). Enhancing public awareness and implementing effective interventions are crucial steps to mitigate the impact of these risk factors on the population's cardiovascular health in the UAE.
Technological Advancements
Technological advancements play a pivotal role in shaping the UAE's interventional cardiology devices market, driving innovation and improving patient outcomes. One of the most significant advancements is the development of drug-eluting stents (DES), which release medication to prevent restenosis (re-narrowing of arteries) following angioplasty. DES technology has significantly reduced the need for repeat procedures and improved long-term efficacy compared to bare-metal stents. Advancements in imaging technologies such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) enhance the precision of procedures by providing detailed images of blood vessels, aiding in stent placement and optimizing treatment outcomes. These imaging modalities help cardiologists assess plaque burden, vessel dimensions, and stent apposition accurately.
Robotic-assisted interventions are gaining traction, offering enhanced dexterity and control during procedures, thereby reducing procedural risks and improving patient safety. Miniaturization of devices, including microcatheters and guidewires, enables access to complex anatomies and facilitates navigational challenges in intricate vascular pathways.
The technological advancements in interventional cardiology devices not only enhance procedural efficiency but also expand treatment options for complex cardiovascular conditions. As these innovations continue to evolve, they are expected to drive further growth and differentiation within the UAE's interventional cardiology devices market, supporting its position as a leader in cardiovascular care in the region.
Growing Healthcare Infrastructure
The UAE's growing healthcare infrastructure is a significant catalyst for the expansion of the interventional cardiology devices market. The country has made substantial investments in building modern hospitals, specialized cardiac centers, and advanced catheterization labs equipped with state-of-the-art imaging and interventional technologies. This infrastructure expansion not only enhances the capacity to deliver high-quality cardiovascular care but also supports the adoption of cutting-edge interventional cardiology devices.
The presence of world-class healthcare facilities in cities like Dubai and Abu Dhabi attracts a diverse patient population, including local residents and international medical tourists seeking specialized cardiac treatments. These facilities offer comprehensive cardiac services, ranging from diagnostic procedures to complex interventional therapies, ensuring timely and effective management of cardiovascular conditions. For instance, In August 2022, Thumbay University Hospital, a leading healthcare provider in the UAE, unveiled a cutting-edge facility dedicated to addressing chest pain concerns among patients facing life-threatening events. The center offers comprehensive non-invasive cardiac diagnostic services encompassing coronary catheterization, EKG-ECG monitoring, stent follow-up, 24-hour Holter monitoring, dobutamine stress echocardiography, Ex-ECG, congestive heart failure diagnosis and management, complete executive physicals, exercise stress tests, cholesterol treatment, as well as carotid and peripheral doppler assessments.
UAE government's initiatives to promote healthcare excellence and innovation through regulatory support and investment incentives further bolster the growth of the interventional cardiology devices market. The continuous expansion and upgrading of healthcare infrastructure across the Emirates contribute to improved accessibility, affordability, and quality of cardiovascular care, reinforcing the UAE's position as a leading hub for advanced medical treatments in the region.
Increasing Healthcare Expenditure
The increasing healthcare expenditure in the UAE has a profound impact on the interventional cardiology devices market, driving growth and innovation in cardiovascular care. As the population grows and ages, coupled with rising incidences of chronic diseases like cardiovascular conditions, there is a heightened demand for advanced medical treatments and technologies. This includes interventional cardiology devices such as angioplasty stents, catheters, and imaging systems, which are essential for diagnosing and treating complex cardiovascular diseases. The UAE's rising healthcare expenditure reflects investments in expanding healthcare infrastructure, upgrading medical technologies, and enhancing healthcare services to meet international standards. These investments not only improve patient outcomes but also support the adoption of state-of-the-art interventional cardiology devices across the country's healthcare facilities. The increased healthcare expenditure facilitates access to specialized cardiac care, including interventional procedures, for both residents and medical tourists. This growth is further propelled by the government's commitment to healthcare excellence through regulatory frameworks that promote innovation and ensure patient safety. Overall, rising healthcare expenditure in the UAE underscores a commitment to advancing cardiovascular care, positioning the market for sustained expansion and technological advancement in interventional cardiology devices.
Key Market Challenges
Regulatory Environment
The regulatory environment in the UAE's interventional cardiology devices market plays a crucial role in shaping market dynamics and ensuring patient safety. The Emirates Authority for Standardization and Metrology (ESMA) and the Ministry of Health and Prevention (MOHAP) oversee the regulation and approval of medical devices, including interventional cardiology devices, ensuring they meet stringent quality and safety standards.
Challenges in the regulatory environment include navigating complex approval processes for new devices, which can involve rigorous testing, clinical trials, and documentation requirements. Companies entering the market must comply with local regulations and obtain necessary certifications, such as the Conformity Assessment Certificate (CAC) and Registration Certificate, before commercializing their products.
Harmonizing UAE regulations with international standards is also important for facilitating market access and promoting innovation. Alignment with recognized regulatory frameworks like the CE Mark (European Conformity) or FDA (Food and Drug Administration) approvals can streamline the approval process for multinational manufacturers. Continuous updates and amendments to regulatory guidelines ensure that interventional cardiology devices in the UAE adhere to evolving technological advancements and global best practices. This regulatory oversight aims to protect patient safety, maintain healthcare quality standards, and foster a competitive marketplace for innovative medical technologies.
Cost Constraints
Cost constraints present significant challenges within the UAE interventional cardiology devices market, impacting both healthcare providers and patients. The high costs associated with advanced interventional procedures and devices, such as angioplasty stents and imaging technologies, can pose barriers to accessibility and affordability. Healthcare facilities must contend with the expense of acquiring and maintaining state-of-the-art equipment, as well as the costs of training personnel to operate these technologies effectively. For patients, out-of-pocket expenses for interventional cardiology procedures can be substantial, particularly if they lack comprehensive insurance coverage. This financial burden may deter individuals from seeking timely medical interventions or opting for less invasive treatments, potentially compromising their health outcomes. The pricing strategies of medical device manufacturers and distributors influence overall healthcare expenditures. Negotiating competitive pricing and cost-effective solutions becomes crucial for healthcare providers striving to deliver quality care while managing budget constraints. Addressing cost constraints requires collaborative efforts among stakeholders, including government entities, healthcare providers, insurers, and manufacturers. Initiatives to streamline procurement processes, negotiate favorable pricing agreements, expand insurance coverage, and promote cost-effective technologies are essential to enhance affordability and ensure equitable access to interventional cardiology devices and procedures in the UAE.
Key Market Trends
Minimally Invasive Procedures
Minimally invasive procedures represent a significant trend in the UAE's interventional cardiology devices market, revolutionizing the treatment of cardiovascular diseases. These procedures involve accessing the heart and blood vessels through small incisions or punctures, rather than traditional open-heart surgery. Key advancements include percutaneous coronary interventions (PCI), such as angioplasty and stent placement, which are performed using catheters guided by imaging technologies like fluoroscopy and intravascular ultrasound (IVUS). Minimally invasive techniques offer several advantages over traditional surgery, including reduced recovery times, shorter hospital stays, lower risk of complications, and quicker return to normal activities for patients. This approach aligns with patient preferences for less invasive treatments that minimize discomfort and downtime. In the UAE, the adoption of minimally invasive procedures is supported by the presence of advanced catheterization labs equipped with state-of-the-art imaging and navigation systems. These facilities enable cardiologists to perform complex interventions with high precision and safety.
As technological innovations continue to enhance the capabilities of minimally invasive devices and techniques, their popularity is expected to grow, driving market demand for specialized interventional cardiology devices tailored to support these procedures effectively.
Structural Heart Interventions
Structural heart interventions are a significant and growing segment within the UAE's interventional cardiology devices market, focusing on treating complex heart conditions without the need for open-heart surgery. These interventions address structural abnormalities or defects of the heart, such as valve disorders and congenital heart defects, using minimally invasive techniques. Transcatheter procedures like transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR) are among the most prominent structural heart interventions. TAVR involves replacing a diseased aortic valve with a prosthetic valve delivered via a catheter, typically through the femoral artery, minimizing the need for sternotomy and reducing recovery times. TMVR, on the other hand, repairs the mitral valve using specialized devices delivered via catheters, addressing issues like mitral regurgitation. These procedures are gaining traction in the UAE due to their effectiveness in treating high-risk patients who may not be suitable candidates for traditional surgery. The country's advanced healthcare infrastructure, including specialized cardiac centers equipped with cutting-edge imaging technologies and skilled interventional cardiologists, supports the growth of structural heart interventions. As the population ages and cardiovascular diseases become more prevalent, the demand for these minimally invasive treatments is expected to rise, driving innovation and investment in interventional cardiology devices tailored for structural heart interventions in the UAE.
Segmental Insights
Product Type Insights
Based on the Product Type, Angioplasty Stents have asserted dominance in the UAE Interventional Cardiology Devices Market. angioplasty stents are dominant in the field of cardiovascular interventions. Stents are crucial as they provide structural support to arteries following angioplasty, which involves opening narrowed or blocked blood vessels to improve blood flow. Their dominance stems from their essential role in treating coronary artery disease, a prevalent condition in the UAE and globally. Stents help maintain vessel patency and reduce the risk of re-narrowing (restenosis) post-procedure, thereby improving long-term outcomes for patients. Advancements in stent technology, including drug-eluting stents that release medication to prevent restenosis, have significantly enhanced their efficacy and safety. This has solidified their position as a preferred choice in cardiovascular interventions. The increasing adoption of minimally invasive procedures and the growing prevalence of lifestyle-related diseases contribute to the sustained demand for angioplasty stents in the UAE and worldwide, making them a dominant category within the cardiovascular device market.
Regional Insights
Dubai stand out as dominated in the UAE's interventional cardiology devices market for several compelling reasons. The city boasts a robust healthcare infrastructure that includes world-class hospitals, specialized cardiac centers, and advanced catheterization labs equipped with cutting-edge interventional technologies. These facilities attract top-tier medical professionals and specialists, making Dubai a preferred destination for complex cardiac procedures, including interventional cardiology treatments.
Dubai's strategic geographical location and excellent connectivity serve as a gateway for medical tourism from neighboring countries and globally. The city's reputation for quality healthcare services and state-of-the-art medical facilities draws a diverse patient population seeking advanced treatments, including minimally invasive interventional cardiology procedures. Dubai's proactive healthcare policies and regulatory frameworks support innovation and investment in medical technologies. The government's initiatives to promote Dubai as a hub for medical excellence and innovation encourage the adoption of advanced interventional cardiology devices and procedures. This environment fosters competition among healthcare providers, driving continuous improvements in patient care and outcomes. The presence of international healthcare partnerships and collaborations enhances Dubai's capabilities in offering the latest interventional cardiology technologies and techniques. These collaborations facilitate knowledge exchange, training programs, and access to innovative medical devices, further solidifying Dubai's leadership in the interventional cardiology devices market within the UAE.
Dubai's combination of advanced healthcare infrastructure, strategic location, supportive regulatory environment, and international collaborations positions it as a dominant force in the UAE's interventional cardiology devices market, catering not only to local residents but also to a global clientele seeking state-of-the-art cardiac care.
Key Market Players
Medtronic Meta FZ-LLC
Boston Scientific Corporation
Abbott Laboratories, S.A.
Biotronik UAE
Edwards LifeSciences UAE
B. Braun Medical Gulf FZ-LLC
Terumo Middle East FZE
Cook Medical UAE
Vasmed UAE
Life Mate Medical Equipment Trading LLC
Report Scope:
In this report, the UAE Interventional Cardiology Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
UAE Interventional Cardiology Devices Market, By Product Type:
o Angioplasty Balloons
o Angioplasty Stents
o Structural Heart Devices
o Catheters
o Plaque Modification Devices
o Hemodynamic Flow Alteration Devices
o Others
UAE Interventional Cardiology Devices Market, By End User:
o Hospitals & Clinics
o Ambulatory Surgery Centers
o Others
UAE Interventional Cardiology Devices Market, By Region:
o Abu Dhabi
o Dubai
o Sharjah
o Rest of UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the UAE Interventional Cardiology Devices Market.
Available Customizations:
UAE Interventional Cardiology Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Impact of COVID-19 on UAE Interventional Cardiology Devices Market
4. Executive Summary
4.1. Overview of the Market
4.2. Overview of Key Market Segmentations
4.3. Overview of Key Market Players
4.4. Overview of Key Regions/Countries
4.5. Overview of Market Drivers, Challenges, Trends
5. Voice of Customer
6. UAE Interventional Cardiology Devices Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type (Angioplasty Balloons, Angioplasty Stents, Structural Heart Devices, Catheters, Plaque Modification Devices, Hemodynamic Flow Alteration Devices, Others)
6.2.2. By End User (Hospitals & Clinics, Ambulatory Surgery Centers, Others)
6.2.3. By Region
6.2.4. By Company (2023)
6.3. Market Map
7. Dubai Interventional Cardiology Devices Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By End User
8. Abu Dhabi Interventional Cardiology Devices Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By End User
9. Sharjah Interventional Cardiology Devices Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By End User
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Merger & Acquisition (If Any)
11.2. Product Launches (If Any)
11.3. Recent Developments
12. Policy & Regulatory Landscape
13. UAE Economic Profile
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Medtronic Meta FZ-LLC
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. Boston Scientific Corporation
15.3. Abbott Laboratories, S.A.
15.4. Biotronik UAE
15.5. Edwards LifeSciences UAE
15.6. B. Braun Medical Gulf FZ-LLC
15.7. Terumo Middle East FZE
15.8. Cook Medical UAE
15.9. Vasmed UAE
15.10. Life Mate Medical Equipment Trading LLC
16. Strategic Recommendations
17. About Us & Disclaimer
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.